Lund, Sweden – 10 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of a peer-reviewed article in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). The paper presents preclinical data on ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5 developed using Alligator’s proprietary Neo-X-Prime™ platform and RUBY ™ format.
The study, titled “ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell dependent tumor immunity and synergizes with PD-1 blockade”, highlights the potential of ATOR-4066 to overcome key resistance mechanisms in the tumor microenvironment. The data demonstrates that ATOR-4066 induces localized activation of myeloid cells and T cells within the tumor, while sparing healthy peripheral tissues, resulting in potent antitumor immunity.
Key findings from the publication include:
- Tumor-localized activation: ATOR-4066 selectively activated CD40 in human tumor samples.
- Potential to outperform other tumor targeting therapies: ATOR-4066 mediates strong anti-tumor activity also in tumors with heterogenous CEACAM5 expression.
- Turning the tumor hot: Mechanistic analyses shows that ATOR-4066 efficiently activates the immune system in the tumor resulting in tumor rejection.
- Synergy with checkpoint blockade: ATOR-4066 demonstrated synergistic activity with anti-PD-1 treatment.
“Publication of these data in Cancer Immunology Research underscores the potential of our Neo-X-Prime platform and RUBY format to generate bispecific antibodies capable of reshaping the tumor microenvironment and driving durable immune responses,” said Søren Bregenholt, CEO of Alligator Bioscience. “As a follow-on to mitazalimab, ATOR-4066 represents a promising new therapeutic strategy for CEACAM5-expressing tumors and provides further evidence of Alligator’s strength in developing tumor-targeted CD40 agonists.”
The full article is available online through >>this link<<.